A stroke-preventing pill from Pfizer Inc. PFE -0.99% and Bristol-Myers Squibb Co. BMY -0.75% won approval from U.S. health regulators Friday, setting the stage for a fierce fight among drug makers to replace the widely used bloodthinner warfarin.
BMS has it in their rules that no contract reps can sell it. Lets remember they let not only us go but nearly all the P4s too. They let 700 go.
Can anyone tell me why they're laying off so many reps NOW, when we need reps to sell Eliquis? This doesn't make sense to me.
My guess is that they want to produce as much revenue as possible with the least amount of cost. It's just like any other business. We have our work cut out for us. Many doctors have been burned by pradaxa and xalreto. And we don't even have all the indications we want/need.
timing was impeccable. Already writing down expectations ahead of launch. They knew the FDA approval was forthcoming in 2012.